Government prescription drug pricing policy and the interplay with investment in life sciences – International Bar Association

Linda Pissott Reig, shareholder in the firm's FDA/Biotech and Life Sciences practice groups, convened a group of experts from the around the world and served as the moderator of the International Bar Association’s (IBA) Healthcare & Life Sciences Committee’s program “Government prescription drug pricing policy and the interplay with investment in life sciences.” During the webinar, the speakers focused on a brief overview of key attributes and updates relating to their region’s approach to the pricing of medicine.

The speakers will consider how updated government policies are impacting:

• the direction of scientific research; and
• investment by private and public entities

This topic is important no matter where a company is located. The industry is now witnessing the seismic impact of new strategies by governments to reign in prices for prescription drugs and biologics. Panelists addressed how policies around the world are transforming how the life sciences industry values products and assesses which products warrant continued research and development. 

Panelists included: 

Tim Wilsdon, Charles River Associates, London, England

Kristin Wall, Norton Rose Fulbright, Toronto, Ontario, Canada

Frank Zhou, JunHe LLP, Shanghai, China; Membership Officer, Healthcare and Life Sciences Law Committee

Sally Shorthorse, Bird & Bird, London, England

For more details and to find a recording of the event (password required), click here.